Immuneering (IMRX) Income from Non-Controlling Interests (2022 - 2026)
Immuneering's (IMRX) quarterly Income from Non-Controlling Interests came in at -$322337.0 in Q1 2026, down 496.32% quarter-over-quarter from $81332.0 in Q4 2025.
Immuneering (IMRX) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
Immuneering's Income from Non-Controlling Interests history runs 5 years deep, the most recent figure standing at -$322337.0 for Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests changed N/A year-over-year to -$322337.0 in Q1 2026; TTM through Mar 2026 was -$241005.0, a 22353.46% decrease from a year earlier, with the FY2025 full-year figure at $81332.0, up 10353.98% from the prior year.
- Income from Non-Controlling Interests slipped to -$322337.0 in Q1 2026 per IMRX's latest filing, from $81332.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $112353.0 in Q4 2022 and bottomed at -$322337.0 in Q1 2026.
- The 5-year median for Income from Non-Controlling Interests is $389.0 (2024), against an average of -$13714.1.
- Across the five-year window, Income from Non-Controlling Interests tumbled 105.68% in 2023 and surged 1136.6% in 2025, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at $112353.0 in 2022, then plunged by 105.68% to -$6385.0 in 2023, then fell by 22.88% to -$7846.0 in 2024, then jumped by 1136.6% to $81332.0 in 2025, then tumbled by 496.32% to -$322337.0 in 2026.
- Per Business Quant, the three latest IMRX Income from Non-Controlling Interests figures stand at -$322337.0 (Q1 2026), $81332.0 (Q4 2025), and -$7846.0 (Q4 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Immuneering | 283.85 Mn | 283.85 Mn | - | -322,337.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -322,337.00 |
| Dec 31, 2025 | 81,332.00 |
| Dec 31, 2024 | -7,846.00 |
| Sep 30, 2024 | 7,845.00 |
| Jun 30, 2024 | 1,084.00 |
| Mar 31, 2024 | -306.00 |
| Dec 31, 2023 | -6,385.00 |
| Sep 30, 2023 | 7,825.00 |
| Jun 30, 2023 | -2,724.00 |
| Mar 31, 2023 | 30,626.00 |
| Dec 31, 2022 | 112,353.00 |
| Sep 30, 2022 | 39,088.00 |
| Jun 30, 2022 | -14,166.00 |
| Mar 31, 2022 | -118,386.00 |